3rd Phase of Human Trial of ‘Soberana’ Coronavirus Vaccine jointly produced by Tehran and Havana ended in Babol University of Medical Sciences on 23 May 2021. According to the report of public relations and international office of Babol University of Medical Sciences, the last dose of conjugate vaccine in the third phase of the clinical trial was in Iran was injected at Babol University of Medical Sciences to the last candidate and the file of this phase in the country closed. Dr. Mostafa Javanian (University Vice Chancellor for Health) said: According to the quota for Mazandaran, a total of 6,000 people under the supervision of Mazandaran and Babol Universities of Medical Sciences received this vaccine and will receive the second dose of their vaccine 28 days after the first dose. While appreciating the good participation of the population under the auspices of eight selected universities of medical sciences to participate in this clinical trial, he said: In Mazandaran, a total of 14,335 people registered to participate in this clinical trial, which due to the limited number of vaccines 6,000 of them received vaccinations.
The third phase of the clinical trial of the coronavirus vaccine of the Pasteur Institute of Iran and the Finlay Institute of Cuba is to be studied in seven provinces of Iran and eight universities of medical sciences, including the Babol university of medical sciences and the medical sciences universities of Mazandaran, Isfahan, Yazd, Kerman, Hormozgan, Hamedan and Zanjan provinces. A sum of 24,000 volunteers will go under study in this phase.
In Cuba, 44,000 people are taking part in the third phase of the human trial of the vaccine.